Biogen (BIIB) News Today $159.88 +4.63 (+2.98%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$159.13 -0.75 (-0.47%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BIIB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Is Global Expansion of LEQEMBI Enough to Reinforce Biogen’s (BIIB) Long-Term Pipeline Strength?October 3 at 8:45 AM | finance.yahoo.comBIIB Stock: Is Biogen Still A Buy After The 14% Spike?October 3 at 8:45 AM | forbes.comBiogen Inc. $BIIB Shares Sold by Robeco Institutional Asset Management B.V.October 3 at 4:36 AM | marketbeat.comGreenleaf Trust Raises Holdings in Biogen Inc. $BIIBOctober 3 at 3:46 AM | marketbeat.comJefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PTOctober 1, 2025 | insidermonkey.comBiogen (NASDAQ:BIIB) Trading 8.1% Higher - Still a Buy?October 1, 2025 | marketbeat.comGenerali Investments CEE investicni spolecnost a.s. Buys 11,695 Shares of Biogen Inc. $BIIBOctober 1, 2025 | marketbeat.comSignaturefd LLC Has $574,000 Stake in Biogen Inc. $BIIBOctober 1, 2025 | marketbeat.comBiogen Inc. (NASDAQ:BIIB) Receives Average Rating of "Hold" from AnalystsSeptember 30, 2025 | americanbankingnews.comBiogen Inc. (NASDAQ:BIIB) Receives Average Rating of "Hold" from BrokeragesSeptember 30, 2025 | marketbeat.comBiogen Inc. $BIIB Stake Raised by Fifth Third BancorpSeptember 29, 2025 | marketbeat.comBiogen (NASDAQ:BIIB) Rating Increased to Strong-Buy at Wall Street ZenSeptember 29, 2025 | americanbankingnews.comEisai, Biogen announce LEQEMBI approved by NMPA in ChinaSeptember 29, 2025 | msn.com“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in ChinaSeptember 28, 2025 | financialpost.comFEisai and Biogen Announce Approval of LEQEMBI® for Maintenance Dosing in Alzheimer's Disease Treatment in ChinaSeptember 28, 2025 | quiverquant.comQ“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in ChinaSeptember 28, 2025 | globenewswire.comBiogen Inc. (BIIB): A Bull Case TheorySeptember 28, 2025 | finance.yahoo.comBiogen Inc. (BIIB): A Bull Case Theory September 28, 2025 | insidermonkey.comGuardian Investment Management Lowers Stock Position in Biogen Inc. $BIIBSeptember 28, 2025 | marketbeat.comBiogen (NASDAQ:BIIB) Stock Rating Upgraded by Wall Street ZenSeptember 28, 2025 | marketbeat.comBiogen (BIIB): Reevaluating Valuation Following FDA’s Supplemental Spinraza Dose SetbackSeptember 27, 2025 | finance.yahoo.comAssenagon Asset Management S.A. Trims Stock Position in Biogen Inc. $BIIBSeptember 27, 2025 | marketbeat.comWealth Enhancement Advisory Services LLC Buys 8,818 Shares of Biogen Inc. $BIIBSeptember 27, 2025 | marketbeat.comBiogen (BIIB) Expands Neurology Pipeline With Alcyone Buyout, Stock Seen UndervaluedSeptember 27, 2025 | msn.comBiogen (NASDAQ:BIIB) Coverage Initiated at Jefferies Financial GroupSeptember 27, 2025 | americanbankingnews.comBanque Pictet & Cie SA Acquires 3,751 Shares of Biogen Inc. $BIIBSeptember 26, 2025 | marketbeat.comBiogen (NASDAQ:BIIB) Given "Outperform" Rating at William BlairSeptember 26, 2025 | americanbankingnews.comJefferies Initiates Coverage of Biogen (BIIB) with Buy RecommendationSeptember 25, 2025 | msn.comBiogen Faces FDA Setback On High-Dose Nusinersen Filing For Spinal Muscular AtrophySeptember 25, 2025 | benzinga.comJefferies Financial Group Begins Coverage on Biogen (NASDAQ:BIIB)September 25, 2025 | marketbeat.comGiant Biogene’s Controlling Shareholder Boosts Stake, Signaling Confidence in Future GrowthSeptember 25, 2025 | tipranks.comBeacon Investment Advisory Services Inc. Reduces Stock Position in Biogen Inc. $BIIBSeptember 25, 2025 | marketbeat.comWhat 6 Analyst Ratings Have To Say About BiogenSeptember 24, 2025 | benzinga.comBiogen Inc. (BIIB) Presents at Bernstein 2nd Annual Global Healthcare Conference TranscriptSeptember 24, 2025 | seekingalpha.comGiant Biogene’s Controlling Shareholder Increases StakeSeptember 24, 2025 | tipranks.comWilliam Blair Reaffirms "Outperform" Rating for Biogen (NASDAQ:BIIB)September 24, 2025 | marketbeat.comBiogen (NASDAQ:BIIB) Receives "Hold" Rating from Needham & Company LLCSeptember 24, 2025 | marketbeat.comLEQEMBI® (Lecanemab) Approved for the Treatment of Alzheimer's Disease in AustraliaSeptember 24, 2025 | globenewswire.comBiogen’s Growth Outlook: Navigating FDA Delays and Pipeline MaturationSeptember 24, 2025 | tipranks.comBiogen’s Hold Rating Maintained Amid Uncertainty Over FDA’s CRL on NusinersenSeptember 24, 2025 | tipranks.comBiogen’s Spinraza High-Dose Application Faces Technical Hurdle, Buy Rating MaintainedSeptember 24, 2025 | tipranks.comUS FDA declines to approve higher dose of Biogen's genetic disorder drugSeptember 23, 2025 | msn.comBiogen Inc.: Biogen Provides Regulatory Update on High Dose Regimen of NusinersenSeptember 23, 2025 | finanznachrichten.deBiogen Inc. Receives Complete Response Letter from FDA for Nusinersen High Dose Regimen in Spinal Muscular AtrophySeptember 23, 2025 | quiverquant.comQUS FDA declines to approve higher-dose of Biogen's genetic disorder drugSeptember 23, 2025 | reuters.comBiogen Provides Regulatory Update on High Dose Regimen of NusinersenSeptember 23, 2025 | globenewswire.comBiogen Inc. $BIIB Shares Acquired by Farmers Trust Co.September 23, 2025 | marketbeat.comArlington Partners LLC Reduces Position in Biogen Inc. $BIIBSeptember 22, 2025 | marketbeat.comIFM Investors Pty Ltd Has $4.49 Million Stock Holdings in Biogen Inc. $BIIBSeptember 22, 2025 | marketbeat.comMn Services Vermogensbeheer B.V. Invests $3.34 Million in Biogen Inc. $BIIBSeptember 21, 2025 | marketbeat.com Get Biogen News Delivered to You Automatically Sign up to receive the latest news and ratings for BIIB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BIIB Media Mentions By Week BIIB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BIIB News Sentiment▼0.970.54▲Average Medical News Sentiment BIIB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BIIB Articles This Week▼1329▲BIIB Articles Average Week Get the Latest News and Ratings for BIIB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Biogen and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Amgen News Today Gilead Sciences News Today Ionis Pharmaceuticals News Today Moderna News Today Prothena News Today Cassava Sciences News Today Vertex Pharmaceuticals News Today Bristol Myers Squibb News Today Eli Lilly and Company News Today Pfizer News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BIIB) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biogen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.